Results of hepatitis B vaccination in sarcoidosis

Mert A., Bilir M., Ozaras R., Tabak F., Karayel T., Senturk H.

RESPIRATION, vol.67, no.5, pp.543-545, 2000 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 67 Issue: 5
  • Publication Date: 2000
  • Doi Number: 10.1159/000067471
  • Journal Name: RESPIRATION
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.543-545
  • Bezmialem Vakıf University Affiliated: Yes


Background: Sarcoidosis is known to be associated with defects in cellular immunity, especially in reference to T helper lymphocytes. Anergy to a tuberculin skin test is most characteristic of this disease. Objectives: To further the data on impaired immunity, we studied the antibody response to hepatitis B vaccination in patients with sarcoidosis, Methods: Serologic markers of hepatitis B virus (HBV) (HBsAg, anti-HBs, anti-HBc) were studied in 40 patients with sarcoidosis (32 female, 8 male; mean age: 45 +/- 11 years, range: 25-66 years) with a mean duration of disease of 6 years, While a II the markers were negative in 22 patients (55%), 2 had isolated anti-HBc positivity and 16 had both anti-HBc and anti-HBs antibodies. Thirty-five age- and sex-matched healthy subjects were studied as controls, Recombinant HBV vaccines (Genhevac B Pasteur, 20 mug) were administered (at 0, 1, and 6 months) to 16 of the seronegative cases and the controls and antibody titres were measured 1 month after the last dose. The tuberculin skin test was negative in all cases. Results: While none of the vaccinees in the diseased group responded, the control group yielded an antibody response rate of 85.7% (30/35), with a mean titre of 257.9 mlU/ml. Conclusions: Patients with sarcoidosis were invariably unresponsive to standard vaccination, while some of the diseased subjects had already mounted a natural antibody response, either before or after the development of the original disease. Cellular immunodeficiency in sarcoidosis could be a suitable model for studying immunological interactions between HBV and the host. Copyright (C) 2000 S. Karger AG, Basel.